· .	OIP			<del></del>	
(REV. 8-83)  MAR 2 9 2004  Patent and Trademark Office		ATTY. DOCKET: 2003080-0138	Į.	APPLICATION NO.: 10/695,582	
		(812 / / / 601/6)		)Z	
	e several sheets if necess		APPLICANT: Danishefsky et al		
(038	e severai sneets ij necessi	ury)	FILING DATE:	GROUP:	
			October 28, 2003	162	-b
and the side of the same	NT DOCUMENTS		T	<del></del>	
Examiner' s Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Yo	6,683,100	Van Hoogevest	January 27, 2004	514	365
	6,670,384	Bandyopadhyay et al.	December 30, 2003	514	365
	6,664,288	Pardee et al.	December 16, 2003	514	449
	6,624,310	Hoefle et al.	September 23, 2003	548	204
1	6,613,912	Hoefle et al.	September 2, 2003	548	204
UC DATE	NT APPLICATIONS	Thomas of al.	Beptember 2, 2005	J-10	2U4
Examiner' s Initials:	Publication Number:	Applicant:	Publication Date:	Group:	Art Unit:
76	2004/0019089	Danishefsky et al.	January 29, 2004		
1	2004/0019088	Lichtner et al	January 29, 2004		
	2004/0018598	Santi et al.	January 20, 2004		-
	2004/0014982	Hoefle et al.	January 22, 2004		
	2004/0014978	Klar et al.	January 22, 2004		
	2004/0006087	Cutler et al.	January 8, 2004		
	2003/0235855	Cabral	December 25, 2003		
	2003/00232837	Guzi et al.	December 18, 2003		
	2003/0232416	Wong et al.	December 18, 2003 -	5,50	
	2003/0232968	Li et al.	December 18, 2003		-
	2003/0191089	Regueiro-Ren et al.	October 9, 2003		
	2003/0187273	White et al.	October 2, 2003		
	2003/0187039	Favreau et al.	October 2, 2003		
,	2003/0186983	Mastalerz et al.	October 2, 2003		
	2003/0186965	Vite et al.	October 2, 2003	سر،	
	2003/0185831	Cutler et al.	October 2, 2003		
	2003/0180760	Basch et al.	September 25, 2003		
	2003/0176710	Klar et al.	September 18, 2003		
	2003/0176473	Taylor et al.	September 18, 2003		
11	2003/0176368	Danishefsky	September 18, 2003		
<u> </u>	2003/0176320	Li et al.	September 18, 2003 **	-	

(REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: IN RE 2003080-0138 APPLICATION (SK-744-CON8) 10/695,582			
l <del>-</del>	ATION DISCLOSURE		APPLICANT: Danisho	efsky et al	
(Use	e several sheets if neces	sary)	FILING DATE:	GROUP	:
	4	· · · · · · · · · · · · · · · · · · ·	October 28, 2003	160	V b
•	2003/0166507	Li et al.	September 4, 2003		
FOREIGN	PATENT DOCUMEN	NTS		ماري د	
Examiner'	Document No.	Country	Date	Translati	on
s Initials				Yes	No
40	EP 1 087 975	Europe	27 August 2003		
	EP 1 042 327	Europe	17 September 2003		
	EP 1 140 944	Europe	27 August 2003	* cr	
	EP 1 340 498	Europe	03 September 2003		
	EP 0 873 341	Europe	10 September 2003		
	WO 2004/007476	PCT	22 January 2004		
,	WO 03/105828	PCT	24 December 2003		
	WO 03/103712	PCT	18 December 2003	* ipr	
	WO 03/084536	PCT	16 October 2003		
	WO 03/078411	PCT	25 September 2003		
	WO 03/077903	PCT	25 September 2003		
	WO 03/076445	PCT	18 September 2003		
	WO 03/075899	PCT	18 September 2003		
	WO 03/074521	PCT	12 September 2003		
	WO 03/074053	PCT	12 September 2003		
$\sqrt{}$	WO 02/074042	PCT	26 September 2002		
OTHER D	OCUMENTS			المشاء	
Examiner' s Initials	Citation (Including A	uthor, Title, Date, Pertinent	Pages, Etc.)		,
" "		2 / /		·	<del>-, </del>
EXAMINE	R T. A.	Solola	DATE CONSID	ERED 8	125/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET: 2003080-0138 (SK-744-CON8)	Unassigne	TION NO.:	
	TION DISCLOSURE several sheets if neces.	•	APPLICANT: Danishefsky et al		
(0363			l .	FILING DATE: GROUP: October 28, 2003	
		October 28, 2003	16.	L b	
Examiner's	U.S. Patent No.	A1:	Trans D.		
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
70	*6,090,601	Gustafsson	July 18, 2000	435	183
	*6,096,757	Bishop	August 1, 2000	514	290
	*6,117,659	Ashley	September 12, 2000	435	155
	*6,121,029	Schupp	September 19, 2000	435	183
	*6,211,412	Georg	April 3, 2001	568	309
,	*6,221,641	Khosla	April 24, 2001	435	193
	*6,251,636	Betlach	June 26, 2001	435	76
	*6,262,107	Li	July 17, 2001	514	449
	*6,280,999	Gustafsson	August 28, 2001	435	252.3
	*6,407,103	Nugiel et al.	June 18, 2002	514	232.8
	*6,489,314	Ashley et al.	December 3, 2002	514	183
	*6,498,257	Vite et al.	December 24, 2002	- 548	205
	*6,515,017	Li et al.	February 4, 2003	514	449
	*6,518,421	Li et al.	February 11, 2003	540	462
	*6,525,197	Furstner et al.	February 25, 2003	544	310
	*6,531,497	Nicolaou et al.	March 11, 2003	514	370
,	*6,537,988	Lee	March 25, 2003	514	221
	*6,538,038	Pero et al.	March 25, 2003	514	731
	*6,544,544	Hunter et al.	April 8, 2003	424	424
	*6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	*6,593,115	Vite et al.	July 15, 2003	435	134
	*6,596,875	White et al.	July 22, 2003	548	204
	*6,603,015	Georg et al.	August 5, 2003	548	203
	*6,603,023	Danishefsky et al.	August 5, 2003	549	346
	*6,605,599	Vite et al.	August 12, 2003	514	63
	*6,605,726	Mulzer et al.	August 12, 2003	548	202
	*6,610,736	Klar et al.	August 26, 2003	514	450
V	*6,613,912	Hoefle et al.	September 2, 2003	548	204

edict

(REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0138 (SK-744-CON8)	IN RE APPLICATION NO.: Unassigned	
INFORMATI	ON DISCLOSURE	STATEMENT	APPLICANT: Danishefsky et al	
(Use se	everal sheets if necesso	ary)	FILING DATE:	GROUP:
			October 28, 2003	1626
U.S. PATENT	APPLICATIONS			
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group: Art Unit:
70	*2002/0086812	Schweinfest et al.	July 4, 2002	
	*2002/0091269	Avery	July 11, 2002	
	*2002/0094991	Gallaher	July 18, 2002	÷
	*2002/0115686	Hoogevest	August 22, 2002	
	*2002/0119202	Hunter et al.	August 29, 2002	
	*2002/0137152	Santi et al.	September 26, 2002	
	*2002/0147197	Newman et al.	October 10, 2002	
	*2002/0156110	Arslanian et al.	October 24, 2002	
	*2002/0156289	Georg et al.	October 24, 2002	
	*2002/0164377	Hunter et al.	November 7, 2002	
	*2002/0165258	Lee	November 7, 2002	
	*2002/0165256	Hofmann et al.	November 7, 2002	
	*2002/0165257	Lee	November 7, 2002	
	*2002/0165265	Hunter et al.	November 7, 2002	
	*2002/0165415	Georg et al.	November 7, 2002	•
	*2002/0169125	Leung et al.	November 14, 2002	
	*2002/0169135	Pardee et al.	November 14, 2002	
	*2002/0169190	Bandyopadhyay et al.	November 14, 2002	
	*2002/0177615	Bandyopadhyay et al.	November 28. 2002	
	*2002/0192778	Schupp et al.	December 19, 2002	
	*2002/0193361	Ashley et al.	December 19, 2002	
	*2002/0197261	Li et al.	December 26, 2002	
	*2002/0198141	McChesney et al.	December 26, 2002	
	*2003/0105330	Danishefsky et al.	June 5, 2003	
	*2003/0109500	Pero et al.	June 12, 2003	
	*2003/0166507	Li et al.	September 4, 2003	
	*2003/0158412	Westermann et al.	August 21, 2003	-
	*2003/0149281	Westermann et al.	August 7, 2003	
	*2003/0147807	Li et al.	August 7, 2003	
V	*2003/0144533	Iwasaki et al.	July 31, 2003	

· · · · · · · · · · · · · · · · · · ·					
FORM PTO		Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Paten	t and Trademark Office	2003080-0138	-	TION NO.:
INEODM AT	TION DISCLOSURE	CT ATEMENT	(SK-744-CON8) Unassigned APPLICANT: Danishefsky et al		<u> </u>
	Several sheets if necess				
(050)	coronal oneces is necess	w. <i>y j</i>	FILING DATE:	GROUP:	26
Vn	*2002/01/4/502	W11	October 28, 2003	10	1
YO	*2003/0144523	Klar et al.	July 31, 2003		
	*2003/0139460	Schwede et al.	July 24, 2003		
	*2003/0134883	Myles et al.	July 17, 2003		
	*2003/0130178	Li et al.	July 10, 2003	· · · · · · · · · · · · · · · · · · ·	ļ
	*2003/0130170	Li et al.	July 10, 2003		
	*20003/0124055	Li et al.	July 3, 2003		
	*2003/0125362	Danishefsky	July 3, 2003		
	*2003/0113335	Li et al.	June 19, 2003		
	*2003/0114363	Li et al.	July 3, 2003		
	*2003/0114450	Santi et al.	June 19, 2003		
	*2003/0114504	Webster et al.	June 19, 2003		
	*2003/0114518	Li et al.	June 19, 2003		
	*2003/0096381	Julien et al.	May 22, 2003		
	*2003/0087888	Regueiro-Ren et al.	May 8, 2003	-	
	*2003/0073677	Lee	April 17, 2003		
	*2003/0073617	Li et al.	April 17, 2003		
	*2003/0073615	Li et al.	April 17,. 2003		
	*2003/0073205	Arslanian et al.	April 17, 2003		
	*2003/0069277	Danishefsky et al.	April 10, 2003		
	*2003/0060623	Vite et al.	March 27, 2003		
	*2003/0054977	Kumar et al.	March 20, 2003		
	*2003/0049841	Short et al.	March 13, 2003		
	*2003/0045711	Ashley et al.	March 6, 2003		
	*2003/0036515	Pardee et al.	February 20, 2003		
	*2003/0036177	Strohhacker	February 20, 2003		
	*2003/0023082	Ashley et al.	January 30, 2003		-
	*2003/0004338	Li et al.	January 2, 2003		
	*2003/0004209	Hunter et al.	January 2, 2003		
V	*2003/0003094	Hunter et al.	January 2, 2003		
OREIGN P	ATENT DOCUMEN	TS			
xaminer's	Document No.	Country	Date	Translation	
nitials				Yes	No
		L			1.0

FORM PTO	<b>D-1449</b> U.S. D	Department of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83)	(REV. 8-83) Patent and Trademark Office		2003080-0138	APPLICATION NO.:
			(SK-744-CON8)	Unassigned
li	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Danishefsky et al	
(Use			FILING DATE:	GROUP:
			October 28, 2003	1626
40	*DE 41 38 042	Germany	19 November 1991	
	*DE 41 38 042	Germary	19 November 1991	
	*DE 196 07 702	Germany	29 February 1996	
	*DE 196 36 343	Germany	30 August 1996	
	*DE 196 38 870	Germany	23 September 1996	
	*DE 196 47 580.5	Germany	18 November 1996	
2	*DE 197 01 758	Germany	20 January 1997	
	*DE 197 07 506.1	Germany	25 February 1997	
	*DE 197 13 970	Germany	04 April 1997	
	*DE 197 20 312	Germany	15 May 1997	
	*DE 197 26 627	Germany	17 June 1997	
	*DE 197 35 574	Germany	09 August 1997	
	*DE 197 35 575	Germany	09 August 1997	
	*DE 197 35 578	Germany	09 August 1997	
	*DE 197 44 135	Germany	29 September 1997	
	*DE 197 49 717	Germany	31 October 1997	
	*DE 197 51 200	Germany	13 November 1997	
	*DE 198 13 821	Germany	20 March 1998	
,	*DE 198 21 954	Germany	15 May 1998	
	*DE 198 33 750	Germany	16 July 1998	
	*DE 198 46 493	Germany	09 October 1998	
	*DE 198 30 060	Germany	30 June 1998	
	*DE 198 49 464	Germany	21 October 1998	
	*DE 199 07 588	Germany	22 February 22, 1999	
,	*DE 199 08 763	Germany	18 February 1999	
	*DE 199 08 765	Germany	18 February 1999	
	*DE 199 21 086	Germany	30 April 1999	
	*DE 199 23 001	Germany	13 May 1999	
	*DE 199 30 111	Germany	01 July 1999	
	*DE 199 54 228	Germany	04 November 1999	
1	*DE 199 54 230	Germany	04 November 1999	
	*DE 100 51 136	Germany	16 October 2000	

FORM PTO-1449  U.S. Department of Commerce (REV. 8-83)  Patent and Trademark Office		ATTY. DOCKET: 2003080-0138	IN RE APPLICATION NO.:	
,			(SK-744-CON8) Unassigned	
INFORMA	INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsky et al	
(Use	several sheets if necesso	ary)	FILING DATE:	GROUP:
		October 28, 2003	1626	
40	*DE 100 15 836	Germany	27 March 2000	
	*DE 100 20 517	Germany	19 April 2000	
	*DE 100 20 899	Germany	20 April 2000	
	*EP 1 275 648	Europe	15 January 2003	
	*EP 1 201 666	Europe	02 May 2002	
	*EP 1 201 666	Europe	05 February 2002	
	*EP 1 186 606	Europe	13 March 2002	
	*EP 1 121 364	Europe	13 March 2002	
,	*EP 1 077 980	Europe	19 March 2003	
	*EP 1 001 951	Europe	25 September 2002	The
	*EP 0 975 638	Europe	07 August 2002	
	*EP 0 975 622	Europe	09 October 2002	
	*EP-0-903-348	Europe		No publication date
70	*199 08 760	DE	24 August 2000	
	*199 08 767	DE	19 October 2000	
	*WO 03/070170	PCT	13 February 2002	·mint
	*WO 03/057830	PCT	17 December 2002	
	*WO 03/057217	PCT	13 January 2003	
	*WO 03/053949	PCT	23 December 2002	
	*WO 03/049734	PCT	19 June 2003	
	*WO 03/045324	PCT	05 June 2003	
	*WO 03/042217	PCT	22 May 2003	
	*WO 03/029260	PCT	10 April 2003	
	*WO 03/029195	PCT	10 April 2003	
	*WO 03/026744	PCT	03 April 2003	
	*WO 03/018002	PCT	06 March 2003	
	*WO 03/014068	PCT	20 February 2003	
	*WO 03/014063	PCT	20 February 2003	ni.
	*WO 03/007924	PCT	30 January 2003	
	*WO 02/46196	PCT	13 June 2002	
	*WO 02/42432	PCT	30 May 2002	
	*WO 02/32844	PCT	16 October 2001	

FORM PTO	-1449 U.S. I	Department of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83) Patent and Trademark Office		2003080-0138	APPLICATION NO.:	
			(SK-744-CON8)	Unassigned
	INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsky et al	
(Use several sheets if necessary)		FILING DATE:	GROUP:	
<u></u>	<del></del>	<u> </u>	October 28, 2003	1626
YO	*WO 02/30356	PCT	15 October 2001	
	*WO 02/098868	PCT	14 May 2002	
	*WO 02/080846	PCT	17 October 2002	
	*WO 02/074042	PCT	26 September 2002	
	*WO 02/072858	PCT	27 February 2002	
	*WO 02/072085	PCT	19 September 2002	
	*WO 02/067941	PCT	06 September 2002	
	*WO 02/066038	PCT	06 February 2002	
	*WO 02/066033	PCT	29 August 2002	
	*WO 02/062338	PCT	15 August 2002	
	*WO 02/060904	PCT	08 August 2002	
	*WO 02/058701	PCT	01 August 2002	
	*WO 02/058700	PCT	01 August 2002	
	*WO 02/058699	PCT	01 August 2002	·
	*WO 01/81342	PCT	19 April 2001	
	*WO 01/81341	PCT	19 April 2001	
	*WO 01/73103	PCT	23 March 2001	
	*WO 01/70716	PCT	12 March 2001	
	*WO 01/66154	PCT	09 March 2001	
	*WO 01/64650	PCT	01 March 2001	
	*WO 01/27308	PCT	06 October 2000	
	*WO 01/10412	PCT	02 August 2000	
	*WO 01/92255	PCT	06 December 2001	
	*WO 01/83800	PCT	08 November 2001	
	*WO 01/07439	PCT	24 July 2000	
	*WO 00/71521	PCT	15 May 2000	
	*WO 00/66589	PCT	01 May 2000	
	*WO 00/58254	PCT	23 March 2000	
	*WO 00/57874	PCT	20 March 2000	
	*WO 00/50423	PCT	17 February 2000	
	*WO 00/49021	PCT	18 February 2000	
	*WO 00/49020	PCT	18 February 2000	

FORM PTO	-1449 IIS D	epartment of Commerce	ATTY, DOCKET:	IN RE
(REV. 8-83)		and Trademark Office	2003080-0138	APPLICATION NO.:
(144,14,00)	1 4.0		(SK-744-CON8)	Unassigned
INFORMAT	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Danishefsky et al	
(Use s			FILING DATE:	GROUP:
			October 28, 2003	1626
70	*WO 00/49019	PCT	18 February 2000	
}	*WO 00/047584	PCT	11 February 2000	
	*WO 00/39276	PCT	21 December 1999	
	*WO 00/37473	PCT	20 December 1999	
	*WO 00/31247	PCT	19 November 1999	
	*WO 00/00485	PCT	30 June 1999	
	*WO 99/67253	PCT	21 June 1999	
	*WO 99/67252	PCT	21 June 1999	
	*WO 99/66028	PCT	16 June 1999	
	*WO.99/65913	PCT	18 June 1999	
	*WO 99/59985	PCT	14 May 1999	
	*WO 99/58534	PCT	07 May 1999	
	*WO 99/54330	PCT	14 April 1999	
	*WO 99/54319	PCT	05 April 1999	
	*WO 99/54318	PCT	05 April 1999	
,	*WO 99/43653	PCT	24 February 1999	
	*WO 99/43320	PCT	23 February 1999	
	*WO 99/42602	PCT	17 February 1999	
	*WO 99/39694	PCT	03 February 1999	
	*WO 98/54966	PCT	04 June 1998	
	*WO 98/47891	PCT		
V	*WO 98/25929	PCT	18 June 1998	
			***	d
Examiner's	Citation (Including	Author, Title, Date, Perting	ent Pages, Etc.)	,
Initials	- Chancia (Michaelle 1		····· · · · · · · · · · · · · · · · ·	
>10			bule Stabilizing Antitumo	
70	Some Nonnatural Ai 68: 3026-3042, 2003		harpless' Asymmedtric Ep	oxidation J. Org. Chem,
			ctures – a new class of mi	crotubule inhibitors with
	potent in vivo antitu	mor activity Elsevier Bioc	himica et Biophysica Acta	, 2000v
	*Altmann, et al., "Ep	pothilones and Their Anal	ogs-Potential New Weapo	ns in the Fight Against
	*Altmann, et al., "Sy		valuation of Highly Potent	Analogues of
			ett., 10(24): 2765-2768, 20	

FORM PTO-	1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:	
(222 17.0 00)	244040 4442 24420044444	(SK-744-CON8)	Unassigned	
INFORMATI	ON DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al		
(Use se	everal sheets if necessary)	FILING DATE:	GROUP:	
		October 28, 2003	1626	
	*Altmann, et al., "Epothilones and Related Str		1	
$\forall o$	with Potent in vivo Antitumor Activity" <i>Bioch</i>			
	*Altmann, et al., "Synthetic and Semisynthetic			
	Biological Activity"	or Lepotimones.	Chemistry and	
	Book of Abstracts, 219th ACS National Meetin,	g. San Francisco. CA. Mai	rch 26-30. ORGN-287.	
1	1999.	5, 24.17 , 4.101500, 011, 1.14.	, en 20 00, en en 20,	
-, - l	*Altmann, et al., "Synthesis and Biological Ex	valuation of Aza-Epothilor	nes" ChemBioChem	
	(Angew. Chem. Int. Ed. Engl.), 1(1)/39(3): 67-	70, 2000.		
	*Altmann, et al., "Microtubule-Stabilizing Ag		Important Anticancer	
	Drugs" Curr. Opin. Chem. Biol., 5(4): 424-43			
	*Appendino, et al., "The Synthesis of Epothilo	ones: Highlights from a Ye	ear's Race", Chemtracts,	
	11(9): 678-696, 1998.	from Madified Date to	:1-04	
	*Arslanian, et al., "A New Cytotoxic Epothilo Heterologously Expresssed in Myxococcus xa			
	*Avila, et al., "The Use of Microtubule Poisor			
	1997.	is on Tumor Cons, Cance	ar 5. 10(0). 515-516,	
	*Awada, et al., New Cytotoxic Agents and Mo	plecular-Targeted Therapic	es in the Treatment of	
	Metastatic Breast Cancer Review, 4-15, 2002.			
	*Baik, et al., Diastereoselective Cobalt-Cataly	zed Aldol and Michael Cy	cloreductions,	
	J.Am. Chem.Soc., 123: 5112-5113, 2001.	٠		
	*Balog, et al., "A Novel Aldol Condensation v	. •		
	Improved Total Synthesis of Epothilone B", A			
	*Balog, et al., "Total Synthesis of Epothilone			
	*Bellemin-Laponnaz, et al., "The Kinetic Reso			
	Acylation Catalyst: Application to Natural Pro	oduct Synthesis" Chem. C	ommun., 12: 1009-1010,	
	2000.			
	*Bertinato, et al., "Studies Toward a Synthesis			
	the Acyl Region and Models for Macrocycliza			
	*Beyer, et al., "Metabolic Diversity in Myxob 195, 1999.	аста Вгоспіт. Вгор	mys. Acia, 1445(2): 185-	
	*Biswas, et al., Highly Concise Routes to Epo	thilones: The Total Synthe	esis and Evaluation of	
	Epothilone 490, J. Am. Chem. Soc., 124: 9825		ois and Evaluation of	
	*Blum, et al., "In vivo Metabolism of Epothilo		Jude Mice:	
1	Identification of Three New Epothilone B Met			
T .	Chromatography/Mass Spectrometry/Pandem			
	Spectrom., 15(1): 41-49, 2001.			
	*Bocci, et al., Protracted Low-Dose Effects or			
1	Survival in Vitro Reveal a Selective Antiangio	genic Window for Variou	s Chemotherapeutic	
	Drugs	<u></u>		
	Cancer Research, 62: 6938-6943, 2002.	Constitution of the Co	4 1 11 41 7 1 4	
ļ	*Boddy, et al., Epothilone C. Macrolactonizati	ion and Hydrolysis Are Ca	talyzed by the isolated	
V	Thioesterase Domain of Epothilone Polyketide 2002.	s symmase, J.Am. Chem. So	c., 125: 3428-3429,	
	2002.0	<u> </u>		

FORM PTO-1	<u>-</u>	ATTY, DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:	
		(SK-744-CON8) Unassigned		
	ON DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al		
(Use se	veral sheets if necessary)	FILING DATE:	GROUP:	
		October 28, 2003	1626	
····	*Bode, et al., "Stereoselective Syntheses of Ep	oothilones A and B via Dir	ected Nitrile Oxide	
40	Cycloaddition"			
· · · · · · · · · · · · · · · · · · ·	J. Am. Chem. Soc., 123(15): 3611-3612, 2001.		"	
	*Bode, et al., Stereoselective Syntheses of Epo and Related Studies" J. Org. Chem., 66(19): 6		ile Oxide Cycloadditions	
	*Bornscheuer, et al., "Directed Evolution of an	n Esterase for the Stereose		
	Key Intermediate in the Synthesis of Epothilor			
	*Borzilleri, et al., "A Novel Application of a I			
	to the Regio and Stereoselective Synthesis of Products"	Lactam Analogues of the j	epotitione Natural	
	J. Am. Chem. Soc., 122(37): 8890-8897, 2000.			
	*Broker, et al., Late Activation of Apoptotic F	athways Plays a Negligibl	e Role in Mediating the	
	Cytotoxic Effects of Discodermolide and Epot			
	Cancer Research, 62: 4081-4088, 2002			
	*Brummond, et al "A Novel Application of a			
	Reaction to the Regio- and Stereoselective Sy	nthesis of Lactam Analogu	ies of the Epothilone	
1	Natural Products"  Chemtracts, 14(7): 401-404, 2001.	77.0		
	*Buck, et al., "Epothilones: A New Class of N	ficrotubule-Stabilizing Ag	ents with a Taxol-Like	
ļ	Mechanism of Action, Chemtracts, 11: 671-67		onto with a rater bill	
	*Carlomagno, et al., "The High-Resolution So		lone A Bound to	
	Rubulin: An Understanding of the Structure-A	* 7	Powerful Class of	
	Antitumor Agents" Angew. Chem. Int. Ed., 42: 2			
	*Carlomagno, et al., "Derivation of Dihedral A			
	Correlated Relaxation Rates: A C-C Torsion I A Bound to Tubulin" Angew. Chem. Int. Ed., 42:	_ ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	rbon Atom in Epotniione	
	*Carreira, E., "Discovery and Study of New R		cations in Complex	
	Molecule Assembly" Chimia, 55(10): 818-820		complex	
	*Casas, et al BINOLAM, a Recoverable Chin		I Enantioselective	
	Catalysis: The Asymmetric Synthesis of Cyan			
	*Chappell, et al., "En Route to a Plant Scale S		Antitumor Agent 12,13-	
	Desoxyepothilone B" Org. Letter. 2(11): 163:		1 1 0 1	
	*Chen, et al "Epothilone Biosynthesis: Asse on the EpoB Subunit" <i>Chem. Biol.</i> , 8(9): 899-		lyicarboxy Starter Unit	
	*Chevalier, Epothilones: A New Generation of		Compounds 13-14	
	-		-	
	*Chou, Desoxyepothilone B is curative agains paclitaxel <i>Proc. Natl. Acad. Sci</i> , 95: 15798-158	_	mat are retractory to	
	*Chou, et al., "The Synthesis, Discovery, and Development of a Highly Promising Class of			
	Microtubule Stabilization Agents: Curative E		•	
	Human Tumor Xenografts in Nude Mice" Pro			
	*Chou, et al., "Desoxyepothilone B: An Effica	acious Microtubule-Target	ed Antitumor Agent with	
V	a Promising In Vivo Profile Relative to Epoth	ione B", Proc. Natl. Acad	Sci., <b>95</b> : 9642, 1998.	

FORM PTO-	<b>L</b>	ATTY. DOCKET:	IN RE		
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:		
		(SK-744-CON8)	Unassigned		
	ON DISCLOSURE STATEMENT	APPLICANT: Danishef	sky et al		
(Use se	everal sheets if necessary)	FILING DATE:	GROUP:		
		October 28, 2003	1626		
	*Chou, et al Desoxyepothilone B: An efficac	<u> </u>	antitumor agent with a		
70	promising in vivo profile relative to epothilone	_			
	*Claus, E. et al., "Synthesis of the C1-C9 Segretary				
}	38:8:1359-1362 (1997)	,			
	*Corey, et al., "Chemistry of Diimide. Some )	New Systems for the Hydr	ogenation of Multiple		
	Bonds" Tetrahedron Lett. 347-352 1961.				
	*Correia, et al., "Physiochemical Aspects of T	ubulin-Interacting Antimi	totic Drugs" Curr.		
	Pharm. Des., 7(13): 1213-1228, 2001				
	*Cowden, et al., "Cancer Drugs-Better than Ta	axol? <i>Nature,</i> <b>387</b> : 238-23	9, 1997.		
	*Danishefsky, et al ,"Insights into Long-Ran	ge Structural Effects on th	e Stereochemistry of		
	Aldol Condensations: A Practical Total Synth	- · · ·	F"		
	J. Am. Chem. Soc., 123(22): 5249-5259, 2001.				
,	*Danishefsky, et al., "On the Interactivity of C	Complex Synthesis and Tu	mor Pharmacology in th		
	Drug Discovery Process: Total Synthesis and Comparative In Vivo Evaluations of the 15-Aza				
	Epothilones" J. Org. Chem., 66(12): 4369-437		D 411 361 414		
	*Danishefsky et al., "Chemical Synthesis and				
	Stabilizing Agents with Enhanced Activity Agents. Chem. 21 <sup>st</sup> Century, Ed. Keinan, Wiley-VCH V		Cell Lines and Tumors		
	*Danishefsky, et al., "En Route to a Plant Sca		ing Antitumor Agent		
	12,13- Desocyepothilone B" Org. Letters, 2: 1		ing Antitumor Agent		
	*Danishefsky, et al., "On the Total Synthesis		1 Evaluations of 15 (R)		
	and 15 (S) Aza-dEpoB: A Mitsupobu Inversio				
	Letters, 2: 1637-1639, 2000.	· · · · - · · · · · · · · · · · · · · ·	, <i>g</i>		
	*Danishefsky, et al., "The Total Synthesis and	Antitumor Activity of 12	, 13-Desoxyepothilone		
	F: An Unexpected Solvolysis Problem at C15,				
	Chem., 65(20): 6525-6533, 2000.				
	*Danishefsky, et al "Subtle Variations in the	Long Range Transmission	n of Stereochemical		
1	Information: Matched and Mismatched Aldol	Reactions" Angew. Chem	. Int. Ed., <b>39</b> : 4505-4508		
	2000.	1'			
	*Danishefsky, et al., "Dianion Equivalents Co		opionate Domain of		
	Epothilone B" Tetrahedron Letters, 40: 2263-		Cons Colondinida di a		
l	*Danishefsky, et al., "Remarkable Long Rang Aldol Condensation" <i>Tetrahedron Letters</i> , 40:	2267-2270 1000	iace Selectivity in an		
	*Danishefsky, et al., "The microtubule-stabilization		and B and their decays		
	derivatives induce mitotic arrest and apoptosis	rin human nrostate cancer	cells " Prostate Cancer		
1	And Prostatic Diseases, 2: 41-52, 1999.	and institute problem outloor	vono. I rosinie Cuiller		
	*Danishefsky, "New Chemical synthesis of the	e Promising Cancer Chem	otherapeutic Agent		
1	12,13-Desoxyepothilone B: Discovery of a Su	rprising Long-Range Effe	ct on the		
	Diastereoselective of an Aldol Condensation."	J. Am. Chem. Soc., 121: 7	7050-7062, 1999.		
	*Danishefsky, et al., "A Novel Aldol Condens	ation with 2-Methyl-4-Per	ntenal and the		
	Application to an Improved Total Synthesis of 1998.	Epothilone B", Angew. C	Chem. Int. Ed. 37: 2675,		

FORM PTO-	U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:	
		(SK-744-CON8)	Unassigned	
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs	sky et al	
(Use se	everal sheets if necessary)	FILING DATE:	GROUP:	
		October 28, 2003	1626	
	*Danishefsky, et al., "Epothilones: Microtubu	le Stabilizing Agents with	Enhanced Activity	
40	Against Multidrug-Resistant Cell Lines and To			
`i	Therpaeutique, Vingt-cinqueme serie, Paul Ehr	lich Lecture, Societe de Cl	nimie Therapeutique ,	
	Elsevier, Paris, New York, 25: 187-206, 1999.			
	*Danishefsky, et al., "The Synthesis and Evaluation	-		
	Highly Convergent Route." Tetrahedron Lette			
	*Danishefsky, et al., "Complex Target Oriente			
	Case History in the dEpoB Series" J. Org. Che			
	*Danishefsky, et al., "Desoxyepothilone B is (		umor Xenografts that	
<del></del>	are Refractory to Pacilitaxel", Proc. Nat. Acad		Ding Forming Ol-C-	
1	*Danishefsky, et al., "Remote Effects in Macro Metathesis: An Application to the Synthesis of			
	Chem. Soc. 119: 2733, 1997.	Truny Active Epotimone	Congeners, J. Am.	
		Enothilone B. An Extensio	n of the Suzuki	
	*Danishefsky, et al., "Total Synthesis of (-) - Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure - Activity Relationships of the Epothilones",			
	*Danishefsky, et al., "Structure-Activity Relationships of the Epothilones and the First in Vivo			
	Comparison with Paclitaxel", Angew. Chem. Int. Ed., 7: 824-826, 1997.			
	*De Brabander, et al., "Towards a Synthesis of Epothilone: A Rapid Assembly of the C(1)-C(6) and C(7)-C(12) Fragments", Synlett, 7: 824-826, 1997.			
	*De Brabander, et al., "Towards a Synthesis o			
	*De Brabander, et al., "Towards a Synthesis o		embly of the $C(1)$ - $C(6)$	
	and C(7)-C(12) Fragments" Synlett, 6: 692, 19		D 16 V	
	*Delbaldo, et al., Nouveaux medicamenets dan	ns le cancer bronchique La	Presse Medicate, 31:	
	*Depmark et al. "Cyclopropagation with Dia	zomothano and Pia(Overs	line) Delladium(II)	
	*Denmark, et al., "Cyclopropanation with Dia Complexes", J. Org. Chem. 62:3375-3389, 19:		mic) ranadium(II)	
	*Duthaler, et al., "Enantioselective Aldol Read		Using Titanium-	
	Carbohydrate Complexes", Angew. Chem. Int			
·	*End, et al., "Synthetic Epothilone Analogs w	vith Modifications in the N	orthern Hemisphere and	
	the Heterocyclic Side-Chain-Synthesis and Bio	ological Evaluation" Proc.	ECSOC-3, Proc.	
	ECSOC-4, 1999, 2000, Meeting Date 1999-20			
	Molecular Diversity Preservation International	al: Basel, Switz. 2000, Do	c. No: 134:311010,	
	2000.	*,* ,* , <del>\text{\tin}\text{\ti}\\\ \text{\ti}\text{\tex{\tex</del>	111 01: -	
1	*Essayan, et al., "Successful Parenteral Desen	sitization to Paclitaxel", J.	Allergy Clin, Immunol.	
<del></del>	97: 42-46, 1996. *Finley, et al., "Metathesis vs. Metastasis: The	Chemistry and Dialogue	f The Enothilonas"	
	Chem. Ind. 24: 991-996, 1997.	Chemian's and Diology of	The Epodinones,	
	*Florsheimer, et al., "Epothilones and Their A	nalogues-A New Class of	Promising Microtubule	
	Inhibitors"			
	Expert Opin. Ther. Pat., 11(6): 951-968, 2001			
/	*Frykman, et al., Control of Secondary Metab	olite Congener Distributio	ns via Modulation of the	
· <b>V</b>	Dissolved Oxygen Tension, Biotechnol. Prog.			

<u>e\_5</u>

FORM PTO-	*	ATTY. DOCKET:	IN RE
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:
		(SK-744-CON8)	Unassigned
INFORMATION DISCLOSURE STATEMENT APPLICANT: Danishefsky et al		ky et al	
(Use so	everal sheets if necessary)	FILING DATE:	GROUP:
		October 28, 2003	1626
40	*Fürstner, "Olefin Metathesis and Beyond", An	ngew. Chem. Int. Ed. Engl	. 39: 3013-3043, 2000.
	*Furstner, et al., "Concise Total Syntheses of	Epothilone A and C Based	on Alkyne Metathesis"
	Chem. Commun., 12: 1057-1059, 2001.	3 <i>C</i>	<u> </u>
	*Geng, et al., "Design and Synthesis of De No Agents" Abstr. PapAm. Chem. Soc., 221st, M.	vo Macrocyclic Hybrids a	s Potential Anticancer
	*Georg, et al, "Studies Toward the Synthesis	of Epothilone Affinity La	bels" Book of Abstracts.
	219th ACS National Meeting, San Francisco, C	CA, March 26-30, MEDI-0	75, 2000.
	*Gerlach, et al., "Synthesis of the C(7)-C(17) S Closing Metathesis Reaction", Synlett, 10: 110	8-1110, 1998	_
	*Gerth, et al., "Studies on the Biosynthesis of Monooxygenase" J. Antibiot., 54(2): 144-148,	2001.	-
	*Gerth, et al, "Epothilons A and B: Antifunga	and Cytotoxic Compoun	ds from Sorangium
	cellulosum (Myxobacteria) Production, Physic of Antibiotics, 49-53, 1996.	o-chemical and Biological	Properties, The Journal
	*Gerth, et al., "Studies on the Biosynthesis of Epothilones: The Biosynthetic Origin of Carbon Skeleton" J. Antibiot, 53(12): 1373-1377, 2000.		
	*Giannakakou, et al., "A Common Pharmacop	hore for Epothilone and Ta	axanes: A Molecular
/	Basis for Drug Resistance Conferred by Tubul Acad. Sci., 97(6): 2904-2909, 2000.	in Mutations in Human Ca	incer Cells Proc. Natl.
	*Griffin, et al., Molecular Determinants of Epo	thilone B Derivative (BM	S 247550) and Apo-
	2L/TRAIL-induced Apoptosis of Human Ovar 47, 2003.	ian Cancer Cells, Gynecolo	ogic Oncology, 89: 37-
	*Grubbs, et al., "Ring-Closing Metathesis and Chem. Res. 28: 446-452, 1995.	Related Processes in Orga	nic Synthesis" Acc.
	*Gupta, et al., Understanding Tubulin-Taxol In to Yeast Tubulin <i>PNAS</i> , <b>100</b> : 5394-6397, 2003	teractions: Mutations Tha	Impart Taxol Binding
	*Hamashima, et al., "Highly Enantioselective ( Lewis Acid-Lewis Base Bifunctional Catalyst"	Tetrahedron, 57(5): 805-8	314, 2001.
	*Hardt, et al., "New Natural Epothilones from So ce90/D13: Isolation, Structure Elucidation 2001.	and SAR Studies" J. Nat.	<i>Prod.</i> , <b>64</b> (7): 847-856,
	*Harris, et al., Complex Target-Oriented Synth History in the dEpoB Series J. Org. Chem., 64:	9434-8456, 1999.	
	*Harris, et al., New Chemical Synthesis of the 13-Desoxyepothilone B: Discovery of a Surpris Diastereoselectivity of an Aldol Condensation. *Hayward, et al. "Total Synthesis of Rapamycia	sing Long-Range Effect or J. Am. Chem. Soc., 121: 70	the 050-7062, 1999,
	Macrocyclization Reaction", J. Am. Chem. Soc.	, 11 <b>5</b> : 9345-9346, 1993.	
	*He, et al., Novel Molcules that Interact with M to Taxol Elsevier Science Ltd. DDT, 6: 1153-11	ficrotubules and have Fund 164, 2001.	ctional Activity Similar

FORM PTO-1 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0138	IN RE APPLICATION NO.:
,		(SK-744-CON8)	Unassigned
INFORMATION	ON DISCLOSURE STATEMENT	APPLICANT: Danishefs	sky et al
(Use se	veral sheets if necessary)	FILING DATE:	GROUP:
	•	October 28, 2003	1626
Yo	*He, et al "Novel Molecules that Interact with Microtubules and have Functional Activity Similar to Taxol" Drug Discovery Today, 6(22): 1153-1164,2001.		
	*He, et al., "A Common Pharmacophore for T Activity of a Taxane Molecule Lacking a C-13 2000.		
	*He, Yun et al., "Total Synthesis and Biologic Research Institute Order No.: DA9966202 Fr		
	*Hindpur, et al., "Total Synthesis of Epothilor 2001.	ne A" Tetrahedron Letters,	, <b>42</b> (42): 7341-7344,·
	*Hofle, et al., "Epothilone A-D and Their This Agents, Pure Appl. Chem., 71: 2019-2024, 19	99.	
	*Holland, M., "1. The Synthesis of a Cyclopropyl Taxane Analog via Sequential Diels-Alder Reactions. 2. The Design and Synthesis of Novel Epothilone Analogs" University of		
V	Pennsylvania Order No.: DA9953544 From:		
No date	1	Biological Evaluation of Epothilone Analogs", Book of Dallas, March 29-April 2, ORGN-015. Year?	
40	*Hofle, et al., Epothilone A and B – Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution, Angew. Chem. Int. Ed. Engl, 35: 1567-1569, 1996.		
	*Hofle, et al., "N-Oxidation of Epothilone A-C and O-Acyl Rearrangement to C-19 and C-21 Substituted Epothilones" Angew. Chem. Int. Ed., 38(13/14): 1971-1974, 1999.		
No date	*Inoue, et al., "Design and Synthesis of Taxoi ACS National Meeting, Boston, August 23-27		<u> </u>
10	*Ivin, "Some Recent Applications of Olefin M Catal. A: Chem, 133(1-2): 1998	fetathesis in Organic Syntl	nesis: A Review", J. Mol.
,	*Jaenicke, L., "Epothilone from Amphora" Co	hem. Unserer Zeit (Germa	n), <b>34</b> (4): 257, 2000.
	*Jiang, et al., "Advances in Research on Nov Epothilones" Tianran Chanwu Yanjiu Yu Kaifa		* . /
	*Johnson, et al "Synthesis, Structure Proof, and Biological Activity of Epothilone Cyclopropanes" Org. Lett, 2: 1537-1540, 2000		
	*Julien, et al., "Isolation and Characterization Sorangium Cellulosum" <i>Gene</i> , <b>249</b> (1-2): 153-	160, 2000	
	*Kalesse, et al., "The Formal Total Synthesis 2823, 1999.		
	*Klar, et al., "Epothilones" Book of Abstracts March 26-30, ORGN-288, 2000		
	*Koch, et al., Diastereoselective Titanium End Epothilones Organic Letters, 2(22): 3811-381	4, 2002.	
	*Krische, et al., "Diastereoselective Cobalt-Ca Am. Chem. Soc. 123: 5112-5113, 2001	atalyzed Aldol and Michae	l Cycloreductions" J.

1				<del></del>
FORM PTO-	<del>-</del>		ATTY. DOCKET: 2003080-0138	IN RE APPLICATION NO.:
(REV. 8-83) Patent and Trademark (		K Office	(SK-744-CON8)	Unassigned
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		•	APPLICANT: Danishefsky et al	
			FILING DATE:	GROUP:
			October 28, 2003	1626
*Lee, et al., "BMS-247550: A Novel Epo Paclitaxel but Possessing Superior Antitude 2001.		vel Epothilo Antitumor	one Analog with a Mode o Efficacy" Clin. Cancer Re	f Action Similar to es., 7(5): 1429-1437,
	*Lee, et al., "Synthesis of the C11-Bull. Korean Chem. Soc., 21(12): 1	177-1178,	2000.	
	*Lee, et al., "Synthesis Toward Ep C10 and the Allylic Bromide of C1	1-C21" Bu	ll. Korean Chem. Soc., 20	(4): 403-404, 1999.
	*Lee, et al., "Insights into Long-Ra Condensations: A Practical Total S 5259, 2001.	Synthesis of	Deoxyepothilone F" J. An	n. Chem. Soc. <b>123</b> : 5249
	*Lee, et al., "Total Synthesis and A Unexpected Solvolysis Problem at Chem., 65: 6525-6533, 2000.	C15, Medi	ated by Remote Substituti	on at C21" J. Org.
	*Li, et al., "Synthesis of a Novel Epothilone B Analog as a Potential Photoaffinity Label" Abstr. PapAm. Chem. Soc. 221 <sup>st</sup> , MEDI-137, 2001			
*Li, et al., "Process Development of the Semisynt Analogue"  Abstracts of Papers, 222 <sup>nd</sup> ACS National Meeting,			26-30, ORGN-238, 2001	
	*Lichtner, et al., "Subcellular Distr Acad. Sci. U.S.A., 98(20): 11743-1	ribution of	Epothilones in Human Tur	
	*Lin, et al., "Design, Synthesis and Pharmacophore for Microtubule-St meeting, Anaheim, CA, March 21-	d SAR of N tabilizing A 25, MEDI-(	R of Novel Hybrid Constructs Based on the Common zing Agents" <i>Book of Abstracts, 217<sup>th</sup> ACS National EDI-038</i> , 1999.  Exoid-Epothilone Hybrids Book of Abstracts, 216th	
No date	ACS National Meeting, Boston, A	ugust 23-27		
40	*List, et al., "Proline-Catalyzed Di 2395-2396, 2000.	rect Asymr	netric Aldol Reactions" J	Am. Chem. Soc. 122:
	*Liu, et al., Total Synthesi of Epot Methoxybenzyl Ether of Epothilon	e C Chem.	Eur. J., 8(16): 3747-3756,	2002
*Liu, et al., "Epoxide Opening with Acetylide for Synthesis of Epothilone A C7-7  Tetrahedron Lett. 39(29): 5261-5264, 1998.  *Liu, et al., "Synthesis of the C11-16+C27 Segment of Epothilone A", Chin. Che 35-38, 1998.  *Machajewski, et al., "Chemoenzymic Synthesis of Key Epothilone Fragments" Iss.), 1469-1472, 1999.  *Martin, et al., Marshall, "Total Synthesis of Epothilone", Nat. Biotechnol. 15(3):				
	*Martin, et al "The 12,13-diol Cy Synthesis of Epothilone B and the Chem. Eur. J, 42(47): 8373-8377,	clization A	pproach for a Truly Stered	ocontrolled Total
	*Martin, "How Stable are Epoxide		l Synthesis of Epothilone	B" Angew. Chem. Int. E.

FORM PTO	•	ATTY. DOCKET:	IN RE
(REV. 8-83) Patent and Trademark Office		2003080-0138	APPLICATION NO.: Unassigned
INFORMATION DISCLOSURE STATEMENT		(SK-744-CON8)	
(Use several sheets if necessary)		APPLICANT: Danishef	
(Car are an arresta y reconsury)		FILING DATE: October 28, 2003	GROUP: /6 24
	*May, et al., "Total Synthesis of (-) Epothilone	<u> </u>	<u>'</u>
40	· · · · · · · · · · · · · · · · · ·		
	*McDaid, et al., Validation of the Pharmacody Epothilone B, During a Phase I Clinical Study		
	*Meng, Dongfang, et al., "Chapter I: The Firs		
	Chapter II: The First Total Syntheses of 12-ep		
	University	-	
	Order No.: DA9949022 From: Diss. Abstr. In		
	*Molnar, et al., "The Biosynthetic Gene Clusto Epothilones A and B from Sorangium Cellulos	sum So ce90" Chem. Biol:	, 7(2): 97-109, 2000.
	*Mulzer, et al., "Epothilone B and its Derivativ		_
	Synthesis and Biological Evaluation" Monatsh *Mulzer, et al., "Total Syntheses of Epothilon		
	2000.	es D and D J. Org. Chem	., 03(22), 7430-7407,
	*Mulzer, et al., "A Novel Highly Stereoselecti	ve Total Synthesis of Epo	thilone B and of its
	(12R,13R) Acetonide" Tetrahedron Lett, 41(4)		
1	*Mulzer, et al., "Synthesis of the C(11)-C(20) Segment of the Cytotoxic Macrolide Epothilone		
	B", Tetrahedron Letters", 38(44): 7725-7728, 1997.  *Mulzer, et al "Easy Access to the Epothilone Family-Synthesis of Epothilone B", Tetrahedron		
	Letters, 39(47): 8633-8636, 1998.		
	*Mulzer, "Progress in the Synthesis of Chiral Heterocyclic Natural Products: Epothilone B and		
	Tartrolon B" J. Heterocycl. Chem., 36(6): 1421-1436, 1999.  *Nakamura, S., "Total Synthesis of Antitumor Antibiotic Epothilone Having Same Mechanism		
	of Action with Taxol", Kagaku (Kyoto)", (In J	Antibiotic Epothilone Ha apanese) <b>52</b> (7): 70-71, 199	Ving Same Mechanism
,	*Newman, et al., "Antitumor Efficacy of 26-F	luoroepothilone B Against	Human Prostate Cance
	Xenografts" Cancer Chemother. Pharmacol.,	<b>48</b> (4): 319-326, 2001.	
	*Nicolaou, et al., Recent Developments in the Epothilones	Chemistry, Biology and N	Medicine of the
	Chem. Commun., 1523-1535, 2001.		
	*Nicolaou, et al., "Synthesis and Biological Ev	valuation of 12, 13-cyclop	ropyl and 12,13-
	cyclobutyl Epothilones"		
<del></del>	ChemBioChem (Angew. Chem. Int. Ed. Engl.),		M-4:-: C4
	*Nicolaou, et al., "Recent Developments in the Epothilones" Chem. Commun., 17: 1523-1535,	2001 Biology and	iviedicine of the
	*Nicolaou, et al "Chemical Synthesis and Bio		and trans-12.13-
	cyclopropyl and 12,13-cyclobutyl Epothilones and Related Pyridine Side Chain Analogues" J.		
	Am. Chem. Soc., 123(38): 9313-9323, 2001.		
	*Nicolaou, et al., "Synthesis of 16-desmethyle	pothilone B: Improved M	ethodology for the
	Rapid, Highly Selective and Convergent Const Commun., 6: 519-520, 1999.	uucuon oi Epothilone B a	na Analogs" Chem.
	*Nicolaou, et al., "Total Synthesis of 16-Desm	ethylepothilone B. Enothi	lone B10. Epothilone F
.]/	and Related Side Chain Modified Epothilone E	Analogues", Chem. Eur.	J., 6(15): 2783-2800,
V	2000.		,

FORM PTO-1449 U.S. Department of Commerce		ATTY. DOCKET:	IN RE
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:
		(SK-744-CON8)	Unassigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs	ky et al
(Use se	veral sheets if necessary)	FILING DATE:	GROUP:
		October 28, 2003	1626
	*Nicolaou, et al., "Chemical Synthesis and Bio	ological Properties of Pyric	line Epothilones"
40	Chem. Biol.7(8): 593-599, 2000.		•
	*Nicolaou, et al., "Chemistry, Biology and Me	dicine of Selected Tubulir	Polymerizing Agents"
	Pure Appl. Chem., 71(6): 989-997, 1999.		
	*Nicolaou, K.C. et al. "Synthesis and Biologic		clopropyl-Epothilone A
	and Related Epothilones" Chem. Biol, 5(7): 365		. 7.6 1.00 1 4 1
	*Nicolaou, et al., "Total Synthesis of Epothilo		, <del>-</del> "
	via a Stille Coupling Based Strategy" Bioorg. *Nicolaou, et al., Chemie und Biologie der Ep		
	*Nicolaou, et al., "Probing the Ring Size of Er Angew. Chem. Int. Ed, 37: 81-87, 1998.	othilone: Total Synthesis	01 [14]-, [15]-,[17]-,"
	*Nicolaou, et al., "Total Synthesis of Epothilon	ne F and Analogues with N	Modified Side Chains
	through the Stille Coupling Reaction" Angew.		
	*Nicolaou, et al., Intellectual Screening of Nat		
	1339-1345, 1997.		
	*Nicolaou, K.C. et al., "Total Synthesis of 26-hydroxyepothilone B and related analogu		
	Chem. Commun. 2343-2344 (1997)		
	*Nicolaou, et al., "Chemical Biology of Epothilones", Angew. Chem. Int. Ed., 37: 2014-2045,		
	1998.		
	*Nicolaou, et al., "Ring-Closing Metathesis in the Synthesis of Epothilones and Polyether		
	Natural Products" Top. Organomet. Chem. 1 (Alkene Metathesis in Organic Synthesis)1: 73-104, 1998.		
	*Nicolaou, et al., "The Olefin Methathesis Approach to Epothilone A and its Analogs", J. Am.		
	Chem. Soc. Doc. 119(34): 7960-7973, 1997.		
	*Nicolaou, et al., Synthesis of Epothilones: A and B in Solid and Solution Phase", Nature, 387:		n Phase", Nature, 387:
	268-272, 1997.		
1	*Nicolaou, et al., "Synthesis of Epothilones: A	and B in Solid and Solution	on Phase", Nature, 390:
	100, 1997	1:	
	*Njaardarson, et al., Application of hitherto un epothilone series: novel epothilone analogs by		
	2002.	total syndicsis, Chem. Con	mmun., 2733-2701,
<u> </u>	*Ojima, et al., "New-Generation Taxoids and	Hybrids of Microtubule-St	abilizing Anticancer
1	Agents" Book of Abstracts, 219th ACS Nationa	l Meeting, San Francisco,	CA, March 26-30,
	ORGN-245, 2000.		
	*Ojima, et al., "A Common Pharamcophore fo	•	cts that Stabilize
	Microtubules Proc. Natl. Acad. Sci. U.S.A., 96		
	*Panicker, et al An unusual Reversal of Stere		
	Enantioselective Synthesis of the C1-C6 Segm 7859-7868, 2000.	ent of the Epotimones Te	uranearon, 50(40):
	*Petrache, et al., "The Role of the Microtubule	s in Tumor Necrosis Facto	or-a-Induced Endothelial
	Cell Permeability" Am. J. Respir. Cell Mol. Biol.,		Diaomonai
1	*Pradella, et al Characterisation, Genome Siz		n of the Myxobacterium
V	Sorangium Cellulosum So ce56, Archives of M		

FORM PTO-1	U.S. Department of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:
		(SK-744-CON8)	Unassigned
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Danishefs	sky et al
		FILING DATE:	GROUP:
		October 28, 2003	1626
	*Pryor, et al., The Microtubule Stabilizing Age		Bind in the Taxoid Site
$\sqrt{n}$	Kills Cells Resistant to Paclitaxel and Epothilo		
	Activity Biochemistry, 41: 9109-9115, 2002.		
	*Quitschalle, et al., "Improved Synthesis of the Northern Hemisphere of Epothilone A by a		
	Sharpless Asymmetric Dihydroxylation" Tetro		
ŀ	*Regentin, et al., "Development of a Cost Effe	•	ss in Myxococcus
	Xanthus" Abstr. Pap-Am. Chem. Soc. 221st, Bl	ilana Diagrathagia in Hata	
	*Regentin, et al., Nutrient Regulation of Epoth Production Strains Appl Microbiol Biotechnol		nologous and Native
	*Regueiro-Ren, et al., "Synthesis and Biologic		nilone Aziridines" Oro
1	Lett., 3(17): 2693-2696, 2001.	and a second of the second	
1,	*Regueiro-Ren, et al., SAR and pH Stability o	f Cyano-Substituted Epoth	ilones, Organic Letters,
	4(22): 3815-3818, 2002		
No date	*Reiff, et al., "Progress Toward Total Synthes 215th ACS National Meeting, Dallas, March 2		
<i>/</i>	*Rivkin, et al., Complex Target-Oriented Tota		
$\gamma v$	Discovery of a Highly Promising Family of Second Generation Epothilones, J. Am. Chem. Soc,		
	<b>125</b> : 2899-2901, 2003.		
	*Rivkin, et al., Total Syntheses of [17]- and [1		
	Ring-Closing Metathesis-Based Strategy: Corn	relation of Ring Size with	Biological Activity in
	the Epothilone Series J. Org. Chem., 67: 7737-	oromethyl Substituent in t	he Enothilone Setting:
	*Rivkin, et al., On the Introduction of a Trifluoromethyl Substituent in the Epothilone Setting: Chemical Issues Related to Ring Forming Olefin Metathesis and Earliest Biological Findings		
-	Organic Letters, 4(23): 4081-4084, 2002.		
	*Santi, et al., "An Approach for Obtaining Per		
	Polyketide Synthase Genes: A Search for the 2000.	Epothilone Gene Cluster"	Gene, <b>247</b> (1-2): 97-102,
	*Sawada, et al., "Enantioselective Total Synth	esis of Epothilone A Using	Multifunctional
	Asymmetric Catalysis" Angew. Chem. Int. Ed.	<b>39</b> (1): 209-213, 2000.	
	*Sawada, et al., "Enantioselective Total Synth		
<u> </u>	Asymmetric Catalysis" J. Am. Chem. Soc., 122		
In complete	*Sehroek, Olefin Metathesis by Well-Defined		_
\p'	*Sefkow, et al., "Derivatization of the C12-C1	3 Functional Groups of Ep	othilones A, B, and C,
	Bioorg. Med. Chem., 8: 3031-3036, 1998.	-C 4' CD 4''	411 D
	*Sefkow, et al., "Oxidative and Reductive Transformations of Epothilone A" Bioorg. Med. Chem. 8(21): 3025-3030, 1998		
	*Sefkow, et al., "Substitutions at the Thiazole	Moiety of Enothilone" Ha	terocycles 48(12)
	2485-2488, 1998.	Description of Description of the	101 00 y 0103, <b>10</b> (12).
	*Schinzer, et al., "Total Synthesis of (-)-epothi	lone A" ChemEur. J., 5(	9): 2483-2491, 1999.
	*Schinzer, et al., "Total Synthesis of (-)-epothi		
/	*Schinzer, et al "Synthesis and Biological Ev	aluation of Aza-Epothilon	es" Angew. Chem. Int.
V	Ed. ChemBiochem, 1(1): 67-70, 2000.	-	_

FORM PTO-1	449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:	
		(SK-744-CON8)	Unassigned	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Danishefsky et al		
		FILING DATE:	GROUP:	
		October 28, 2003	1626	
> /	*Schinzer, et al., "Synthesis of Epothilones. St	tereoselective Routes to E	oothilone B" Synlett 8:	
YO	861-864, 1998.	•		
1	*Schinzer, Interview: Epothilones New Prom	- , , , , , , , , , , , , , , , , , , ,	ing Products with	
	Taxol-like Biological Activity, ECC Braunsch			
	*Schinzer, et al., "New and Convenient Synthe	` ,	hyl-3-oxa-5-(tert-	
40	butyldiphenylsilyloxy)methylpentanoate and 2 butyldimethylsiloxy)methylpentanoate" <i>Phosp</i> 2000.		t. Elem., 158: 187-199,	
	*Schneider, et al., Utilzation of Alternate Subs Epothilone Synthetase Assembly Line J. Am. (			
	*Scholl, et al., "Increased Ring Closing Metatl			
	Metathesis Catalysts Coordinated with Imidaz 2247, 1999.	olin-2-Ylidene Ligands" 7	Tetrahedron Lett. 40:	
	*Scudiero, et al., Evaluation of a Soluble Tetra	zolium/Formazan Assay	for Cell Growth and	
	Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines, Cancer Research, 48:			
	4827-4833, 1988.			
	*Shibasaki, et al., "Multifunctional Asymmetric Catalysis" Chem. Pharm. Bull., 49(5): 511-524, 2001.  *Shioji, et al., "Synthesis of C1-C6 Fragment for Epothilone A via Lipase-Catalyzed Optical Paralytics" Synth. Commun. 31(32): 3560-3575-2001			
	Resolution" Synth. Commun., 31(23): 3569-3575, 2001.  *Sinha, et al., "The Antibody Catalysis Route to the Total Synthesis of Epothilones" Proc. Natl.			
	Acad. Sci95(25): 14603-14608, 1998.			
1,	*Sinha, et al., "Catalytic Antibody Route to th		thilones: Total	
V	Synthesis of Epothilones A-F" Chem. Eur. J., 7			
1 1 4	*Sinha, et al "Total Synthesis of Epothilones		gs via Antibody	
No date	Latalysis Ye Book of Abstracts, 217th ACS National Meeting	ar.  Anghaim C4 March 2	1 25 OPCN 054	
	*Sinha, et al., "Synthesis of Epothilone Analog	g, munum, Cri, murch 21	ed Decolution of	
YO	Thiazole Aldol Synthons on a Multigram Scale	e. Biological Consequence	es of C-13 Alkylation of	
,	Epothilones" ChemBioChem, 2(9): 656-665, 2	001.	os of C-13 Aikylation of	
	*Sinha, et al., "Sets of Aldolase Antibodies wi		Formal Synthesis of	
	Epothilone E by Large Scale Antibody-Cataly	zed Resolution of Thiazole	e Aldol" Org. Lett	
	1(10): 1623-1626, 1999.			
	*Sinha, et al., "Regioselective Synthesis of Flu			
	Syntheses via Antibody Catalysis" Tetrahedro	n Letters, 41(43): 8243-82	46, 2000.	
	*Skehan, et al., New Colorimetric Cytotoxicity the National Cancer Institute, 82: 1107-1112,	1990.	_	
	*Smart, Fluorine Substituent Effects (on bioact 2001.		Chemistry, 109: 3-11,	
	*Stachel, et al., "The Epothilones, Eleutherobi	ns, and Related Types of N	Molecules" Curr	
1	Pharm. Des., 7(13): 1277-1290, 2001.	The second of th		
		·		
1/	*Stachel, et al., "Chemo- and Stereoselective I	Epoxidation of 12,13-Deso	xyepothilone B using	

FORM PTO-1			ATTY. DOCKET:	IN RE
(REV. 8-83)	Patent and Tradema	ark Office	2003080-0138	APPLICATION NO.:
		(SK-744-CON8)	Unassigned	
INFORMATION DISCLOSURE STATEMENT APPLICANT: Danishefsky		sky et al		
(Use se	veral sheets if necessary)		FILING DATE:	GROUP:
			October 28, 2003	1626
*Still, et al., "Stereoselective Synthesis of 1,3 Bridge of Rifamycin S" J. Am. Chem. Soc. 10		thesis of 1,3- hem. Soc. 10	Diol Derivatives and App. 5: 2487-2489, 1983.	lication to the Ansa
*Su, et al., Structure – Activity Relationships of the Epothilones and the First In Vivo Comparison with Paclitaxel Angew. Chem. Int. Ed. Engl. 36: 2093-2096, 1997.			1997.	
	*Tamao, et al., "Selective Carbon Reagents with Organic Halides. ( 4374-4379, 1972.	Catalysis by I	Nickel-Phospine Complexe	es" J. Am. Chem Soc. 94
	*Tang, et al., "Cloning and Expre 2000.			r
	*Tang, et al., "Generation of Nov Biotransformation The Journal of	f Antibiotics,	<b>56</b> : 16-23, 2003.	
	*Tanimori, et al., "Simple Synthe Epothilones" <i>Biosci. Biotechnol.</i>	Biochem, 62	(12): 2428-2430, 1998.	
	*Tanimori, et al., "Easy Access to Both Enantiomers of C7-C12 Segment of Epothilones" Synth Commun., 29(24): 4353-4360, 1999.  *Taylor, et al., "Total Synthesis of Epothilones B and D" Org. Lett., 3(14): 2221-2224, 2001  *Taylor, et al., "The Identification of the Biologically Active Conformation of Epothilone"  Book of Abstracts, 217th ACS National Meeting, Anaheim, CA, March 21-25, ORGN-041  *Taylor, et al., "The Conformational Properties of Epothilone"-Erratum J. Org. Chem., 65(17): 5449, 2000.			
<u> </u>				
No date				
Yo				·
	*Taylor, et al., "Conformational 1999.			
	*Taylor, et al., Catalytic Diastere Interdependent Reaction Variable 12202-12203, 1999.			•
,	*Taylor "A Formal Total Synther and C7-C12 Fragments" J. Org.	Chem., <b>63</b> (25	): 9580-9583, 1998.	
	*Ter Haar, et al., "Taxanes and C 8(5): 571-586, 1998.			
	*Trnka, et al., "The Developmen Organometallic Success Story",	Acc. Chem. I	Res. 34: 18-31, 2001.	
	*Trnka, et al., The Development Organometallic Success Story Ac	cc. Chem.Res.	, <b>34</b> : 18-29, 2001.	-
<b>V</b>	*Valluri, et al., "Total Synthesis	<u> </u>		
No date	*Victory, ct al., "Development o National Meeting, Dallas, March	29-April 2,	MEDI-187	
40	*Vite, et al., "Epothilones A and Agents"  Book of Abstracts, 219th ACS Nat 2000.		·	_
	*Von Angerer, E"Tubulin as a Ta	arget for Anti	cancer Drugs" Curr. Opin	. Drug Discovery Dev.,

<del></del>			
FORM PTO-	<b>-</b>	ATTY, DOCKET:	IN RE
(REV. 8-83)	Patent and Trademark Office	2003080-0138	APPLICATION NO.:
		(SK-744-CON8)	Unassigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs	sky et al
(Use se	everal sheets if necessary)	FILING DATE:	GROUP:
		October 28, 2003	1626
	*Walsh, C. "Enzymatic Assembly of Hybrid F		
$\forall 0$	Products" Abstracts of Panars 222nd ACS Nat	ional Maetina Chicago II	I August 26 30 RIOI
	Products" Abstracts of Papers, 222 <sup>nd</sup> ACS National Meeting, Chicago, IL, August 26-30, BIOL-126, 2001		
<del>                                     </del>	*Wessjohann, et al., "Synthesis of Natural-Product-Based Compound Libraries" Curr. Opin.		
ŀ	Chem. Biol., 4: 303-309, 2000.	duot Basea Compound Bi	oranos carr. opin.
	*Wessjohann, et al."Synthetic Access to Epotl	nilones-Natural Products v	vith Extraordinary
	Anticancer Activity" Org. Synth. Highlights II	V Ed: Schmalz, H., Wiley-	VCH Verlab GmbH:
	Weinheim Germany, 251-267, 2000	·	
	*White, et al., Total Synthesis of Epothilone E		d trans-9, 10-
	Dehydroepothilone D, J. Am. Chem. Soc., 125:		
1/	*White, "Total Synthesis of Epothilone B, Epo		ns-9,10-
$-\Psi$	Dehydroepothilone D" J. Am. Chem. Soc., 123		411 700
No date	*White, et al., "Synthetic Approach Towards t		
100 clave	Abstracts, 216th ACS National Meeting, Boston		
40	*White, et al., "Two Coupling Strategies for a Stereoselective Synthesis of Epothilone B" Book		
100	of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-813, 2000.		
	*White, et al., "A Highly Stereoselective Synthesis of Epothilone B" J. Org. Chem., 64(3): 684-685, 1998.		
<del></del>	*White, et al., "Improved Synthesis of Epothilone B Employing Alkylation of an Alkyne for		
	Assembly of Subunits" Org. Lett., 1(9): 1431-1434, 1999.		
	*Winkler, et al., "A Model for the Taxol (Paclitaxel) Epothilone Pharmacophore", Bioorg., Med.		
	Chem. Letter, 6: 2963-2966, 1996.		
	*Winkler, et al., "Design and Synthesis of Constrained Epothilone Analogs: The Efficient		
1	Synthesis of Eleven-Membered Rings by Olefin Metathesis" Tetrahedron, 55(27): 8199-8214,		
	1999.		
	*Winssinger, et al., "Epothilones and Sarcodic		
	Analogs" Book of Abstracts, 219th ACS Nation	aal Meeting, San Francisco	o, CA, March 26-30,
	ORGN-289, 2000.	on Antinnantatia Dasta'	
	*Wittmann, et al., Flavopiridol Down-Regulat Breast Cancer Cells to Epothilone B-induced		
	*Wolff, A., "Epothilone A Induces Apoptosis		
	Mechanisms of Drug Resistance", Int. J. Onco		
	*Woltering, et al., Development of a Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs, Annals of Surgery, 237: 790-800, 2003.		
	*Yang, et al., "Total Synthesis of Epothilone A: The Olefin Metathesis Approach: Angew. Chem.		
,	Int. Ed., 36: 166-168, 1997.	i. The Olemi Metantesis ?	approach, Angew. Chem.
-	*Yoshimura, et al., Synthesis ad Conformation	nal Analysis of (F) 0 10 F	Dehydroenothilone D: A
	Suggestive Link between the Chemistry and B	iai Anarysis or (EJ-2, 10-L iology of Enothilones An	onyuroepoumone B. A.
1 /	2518-2521, 2003.	iology of Epolitiones, And	50w. Onem. 11tt. Eu. 42.
	*Zhou, et al., Brominated Derivatives of Nosci	apine Are Potent Microtuh	ule-Interfering Agents
	That Perturb Mitosis and Inhibit Cell Prolifera	tion, Molecular Pharmaco	logy, 63: 799-807, 2003
	*Zhu, et al., "Methodology Based on Chiral Si	lanes in the Synthesis of P	Olypropionate-Derived

FORM PTO-1	449 U.S. Department of Com	merce ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Of	fice 2003080-0138	APPLICATION NO.:	
	,	(SK-744-CON8)	Unassigned	
	ON DISCLOSURE STATEMENT	APPLICANT: Danishe	fsky <i>et al</i>	
(Use se	veral sheets if necessary)	FILING DATE:	GROUP:	
	·	October 28, 2003	1626	
70	Natural Products-Total Synthesis of Ep	othilone A" Eur. J. Org. Chem.,	9: 1701-1714, 2001.	
vh d L	*Zhu, et al., "Studies Toward the Total		ok of Abstracts, 216th ACS	
No date	National Meeting, Boston, August 23-2			
*Zhu, et al "Enzymatic Resolution of Thiazo				
1,0	C12-C21 Fragment of the Epothilones'			
	*Zhu, et al "Studies Toward the Total			
	National Meeting, San Francisco, CA,	March 26-30, ORGN-060, 2000		
V	*Zhu, et al., "Total Synthesis of Epothi	lone A" Org. Lett., 2(17): 2575-	2578, 2000.	
EXAMINER	T.A. Solola	DATE CONSID	ERED 8/25/04	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line				

through citation if not in conformance and not considered. Include copy of this form with next communication to

3605474

applicant.